

Decision to include Beijing Tong Ren Tang April 2021

Background

Beijing Tong Ren Tang was excluded from KLP and the KLP Mutual Funds in 2019. The company had revenues from production of alcohol that exceeded 5 % of total revenues.

The assessment

The company is a Chinese pharmaceutical company that develops, manufactures, and markets Chinese traditional medicines and medicinal wines. Based on information from MSCI the revenues from production of alcohol have been reduced to 0,99 %. Hence, the ground for exclusion is no longer valid.

KLP's decision

KLP has decided to revoke the exclusion of Beijing Tong Ren Tang from KLP and the KLP Mutual Funds' investments.

Sensitivitet: Begrenset